340B Drug Pricing Program
Several House and Senate committees will hold hearings this week on a variety of issues that affect hospitals and health systems.
The AHA strongly opposes legislation that would lead to additional site-neutral payment cuts and threaten access to patient care, Ashley Thompson, AHA senior vice president of public policy analysis and development, told the House Energy and Commerce Subcommittee on Health today during a hearing …
The health care workforce, 340B Drug Pricing Program and end of the COVID-19 public health emergency are at the forefront of AHA’s discussions with lawmakers, said Stacey Hughes, AHA's executive vice president of government relations and public policy, during the annual meeting opening plenary.
Several House subcommittees April 26 will hold hearings on a variety of issues that affect hospitals and health systems, including transparency, site-neutral payment policies, tax-exempt status, workforce shortages and the Provider Relief Fund.
The 340B program has worked successfully for over 30 years to allow eligible providers to stretch limited federal resources to provide more comprehensive programs and services to more patients. This is exactly what Congress intended when it created the program in 1992.
The AHA appreciates the opportunity to provide the subcommittee with information for its hearing on Examining Existing Federal Programs to Build a Stronger Health Workforce and Improve Primary Care.
For 25 years, the 340B program has provided hospitals with financial help to expand access to life-saving prescription drugs and comprehensive health care services to low-income and uninsured individuals in communities across the country.
The AHA, joined by the Arkansas Hospital Association and 340B Health, April 14 filed an amicus brief in the United States Court of Appeals for the Eighth Circuit defending Arkansas Act 1103 against a constitutional challenge brought by the Pharmaceutical Research and Manufacturers of America (PhRMA…
The AHA, joined by the Arkansas Hospital Association and 340B Health, late Friday filed an amicus brief in the U.S. Court of Appeals for the 8th Circuit defending Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by the Pharmaceutical Research and…
The American Hospital Association (AHA), 340B Health, and the Arkansas Hospital Association told the U.S. Court of Appeals for the Eighth Circuit that Arkansas’s 340B Drug Pricing Nondiscrimination Act does not conflict with federal law but rather supports Congress’s goal in enacting the 340B…